| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2015PLoSO..1032745T |
| P356 | DOI | 10.1371/JOURNAL.PONE.0132745 |
| P932 | PMC publication ID | 4508028 |
| P698 | PubMed publication ID | 26192408 |
| P5875 | ResearchGate publication ID | 281821396 |
| P50 | author | Lisa H. Butterfield | Q41520723 |
| P2093 | author name string | Sandra Lee | |
| Yan Lin | |||
| Ahmad A Tarhini | |||
| Steven Ringquist | |||
| Helen Gogas | |||
| Yongli Shuai | |||
| Cindy Sander | |||
| Sanjiv S Agarwala | |||
| Haris Zahoor | |||
| John M Kirwood | |||
| P2860 | cites work | A four-marker signature of TNF-RII, TGF-α, TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma | Q21245488 |
| Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12 | Q24290619 | ||
| Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains | Q24297459 | ||
| Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo | Q24678892 | ||
| Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
| Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease | Q28201947 | ||
| THE LASSO METHOD FOR VARIABLE SELECTION IN THE COX MODEL | Q29038535 | ||
| The immunobiology of cancer immunosurveillance and immunoediting | Q29616246 | ||
| High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993 | Q29619885 | ||
| Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment | Q30415355 | ||
| Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma | Q30422102 | ||
| Time-dependent ROC curves for censored survival data and a diagnostic marker | Q30600327 | ||
| A functional polymorphism in the promoter/enhancer region of the FOXP3/Scurfin gene associated with type 1 diabetes | Q34197513 | ||
| Human eosinophils express functional interleukin 2 receptors | Q34197541 | ||
| Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon. | Q34269292 | ||
| Interferons alpha and beta as immune regulators--a new look | Q34289965 | ||
| Immune surveillance of tumors | Q34579196 | ||
| Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial | Q34594112 | ||
| On the role of sIL-2R measurements in rheumatoid arthritis and cancers | Q34894394 | ||
| Serologic evidence of autoimmunity in E2696 and E1694 patients with high-risk melanoma treated with adjuvant interferon alfa | Q35020518 | ||
| IFN-α in the treatment of melanoma | Q35572008 | ||
| A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. | Q35617517 | ||
| An update of the HLA genomic region, locus information and disease associations: 2004. | Q35951777 | ||
| Gene map of the extended human MHC. | Q35968433 | ||
| Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients | Q35978475 | ||
| Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. | Q51917147 | ||
| An immune-active tumor microenvironment favors clinical response to ipilimumab | Q56898024 | ||
| L-selectin expression is low on CD34+ cells from patients with chronic myeloid leukemia and interferon-a up-regulates this expression | Q57107854 | ||
| Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response | Q70918943 | ||
| Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma | Q72203307 | ||
| Effects of systemic interferon-alpha (IFN-alpha) on the antigenic phenotype of melanoma metastases. EORTC melanoma group cooperative study No. 18852 | Q72233449 | ||
| Expression of IL-2 receptors in human melanoma cells | Q72797308 | ||
| Interleukin-2 receptors in pulmonary adenocarcinoma tissue | Q73032815 | ||
| High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801 | Q73825066 | ||
| Serum adhesion molecules and interleukin-2 receptor as markers of tumour load and prognosis in advanced cutaneous melanoma | Q74439190 | ||
| Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12 | Q74462977 | ||
| Adjuvant interferon treatment for melanoma | Q77366787 | ||
| Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses | Q79816363 | ||
| Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon alpha treatment | Q36135987 | ||
| Expression of interleukin 2 receptors on activated human B cells | Q36349561 | ||
| Interleukin 10 (IL-10): an immunosuppressive factor and independent predictor in patients with metastatic renal cell carcinoma | Q36617525 | ||
| Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and interleukin-10 serum levels in patients with melanoma | Q36642320 | ||
| Interleukin-12: biological properties and clinical application | Q36910729 | ||
| Melanoma adjuvant therapy | Q38216372 | ||
| Multiplex serum biomarker assessments: technical and biostatistical issues | Q38806499 | ||
| Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma | Q40974941 | ||
| IL-12 regulates VEGF and MMPs in a murine breast cancer model | Q41003453 | ||
| Inhibition of angiogenesis in vivo by interleukin 12. | Q41665801 | ||
| Prognostic significance of autoimmunity during treatment of melanoma with interferon. | Q44019499 | ||
| Receptors for interleukin 2 on human squamous cell carcinoma cell lines and tumor in situ | Q44601747 | ||
| Expression of functional IL 2 receptors by lipopolysaccharide and interferon-gamma stimulated human monocytes. | Q44677540 | ||
| Serum interleukin-6 concentrations as predictive factor of time to progression in metastatic malignant melanoma patients treated by biochemotherapy: a retrospective study | Q44683203 | ||
| The biological significance of soluble interleukin-2 receptors in solid tumors | Q46807742 | ||
| A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma | Q47969082 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | e0132745 | |
| P577 | publication date | 2015-07-20 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Pro-Inflammatory Cytokines Predict Relapse-Free Survival after One Month of Interferon-α but Not Observation in Intermediate Risk Melanoma Patients | |
| P478 | volume | 10 |
| Q47225640 | Advances in Proteomic Techniques for Cytokine Analysis: Focus on Melanoma Research |
| Q36629345 | An inducible transgenic mouse breast cancer model for the analysis of tumor antigen specific CD8+ T-cell responses |
| Q36588833 | Modulation of Cytokines in Cancer Patients by Intravenous Ascorbate Therapy |
Search more.